Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
Twitter Feed
-
At UCB, we’re aiming to reduce our water consumption by 20% by 2030 compared to the 2015 baseline. https://t.co/9yxQkwY6t9
— UCB News (@ucb_news) 18.09.2019 -
Ahead of #ASBMR2019, UCB is proud to work with @JavaidKassim to bring the congress to life! He’ll be providing his thoughts and experiences at the congress. We can’t wait to hear what he has to say! Follow the conversation at #UCBtakeover https://t.co/tFC
— UCB News (@ucb_news) 17.09.2019 -
UCB has been named among the Top 25 companies in the 2019 Refinitiv #Diversity & #Inclusion Index https://t.co/U4zp1p27wV https://t.co/bteDUsBdH2
— UCB News (@ucb_news) 17.09.2019
